药品名称 | DYMISTA | 申请号 | 202236 | 产品号 | 001 | 活性成分 | AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE | 市场状态 | 处方药 | 剂型或给药途径 | SPRAY, METERED;NASAL | 规格 | EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY | 治疗等效代码 | | 参比药物 | 是 | 批准日期 | 2012/05/01 | 申请机构 | MEDA PHARMACEUTICALS
| 化学类型 | New combination | 审评分类 | Standard review drug |
|
|
|
与本品相关的市场独占权保护信息 | 独占权代码 | 失效日期 | NPP | 2018/02/20 | PED | 2018/08/20 | 历史市场独占权保护信息 | NC | 2015/05/01 |
|
与药品注册相关的信息 | 申请号 | 修订号 | 审批结论 | 公开文档类型 | 文档创建时间 | 获取文档 | 202236 | 008 | AP | Label | 2015/02/23 | 下载 | 202236 | 008 | AP | Letter | 2015/02/24 | 下载 | 202236 | 001 | AP | Letter | 2012/08/17 | 下载 | 202236 | 001 | AP | Label | 2012/08/22 | 下载 | 202236 | 000 | AP | Review | 2013/05/06 | 下载 | 202236 | 000 | AP | Summary Review | 2013/05/06 | 下载 | 202236 | 000 | AP | Label | 2012/05/02 | 下载 | 202236 | 000 | AP | Letter | 2012/05/03 | 下载 |
|
药品注册审批历史信息 | 申请号 | 修订号 | 审批结论 | 审批日期 | 审批内容 | 202236 | 008 | AP | 2015/02/20 | Efficacy Supplement with Clinical Data to Support | 202236 | 007 | AP | 2014/10/29 | Manufacturing Change or Addition | 202236 | 005 | AP | 2014/06/02 | Manufacturing Change or Addition | 202236 | 004 | AP | 2014/01/21 | Manufacturing Change or Addition | 202236 | 003 | AP | 2013/03/26 | Manufacturing Change or Addition | 202236 | 002 | AP | 2012/11/19 | Manufacturing Change or Addition | 202236 | 001 | AP | 2012/08/10 | Labeling Revision | 202236 | 000 | AP | 2012/05/01 | Approval |
|